Food and Drug Administration
Oncologic Drugs Advisory Committee
December 13, 1999
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Targretin® Capsules 75mg Bexarotene, Ligand Pharmaceuticals, Inc. pdf
FDA Medical Officer Review Targretin® (Bexarotene) 75mg Capsules Ligand Pharmaceuticals, Inc., Dr. Oluwole Odujinrin, MD htm ppt
Introduction NDA 20-449/SE011 Taxotere® (docetaxel) for Injection Concentrate, Dr. Philip Chaikin, PharmD, MD, Rhône-Poulenc Rorer Pharmaceuticals htm ppt
NDA 20-449 SE-011 Docetaxel, FDA Review htm ppt